| abstract |
A medicinal composition containing a gp34 binding inhibitor as the active ingredient for treating autoimmune diseases including rheumatism, multiple sclerosis, sarcoidosis, autoimmune ophthalmic diseases and inflammatory bowel disease or graft-versus-host disease. It has been experimentally confirmed that the onset of pathological conditions in rheumatism models and multiple sclerosis models can be inhibited by administering an antimouse gp34 rat monoclonal antibody to model mice for inducing collagen arthritis and those for inducing experimental autoimmune encephalomyelitis. |